


Claims:

1. A method for treating female sexual dysfunction comprising:  
administering to a female subject in need thereof, an effective amount of an  
5 estrogen agonist / antagonist, and optionally,  
co-administering an effective amount of a cyclic guanosine 3',5'-  
monophosphate elevator.
2. A method as in claim 1 wherein said estrogen agonist / antagonist of the  
10 following formula (I):



wherein:

- A is selected from  $\text{CH}_2$  and  $\text{NR}$ ;
- 15 B, D and E are independently selected from CH and N;
- Y is
  - (a) phenyl, optionally substituted with 1-3 substituents independently selected from  $\text{R}^4$ ;
  - (b) naphthyl, optionally substituted with 1-3 substituents  
20 independently selected from  $\text{R}^4$ ;
  - (c)  $\text{C}_3\text{-C}_8$  cycloalkyl, optionally substituted with 1-2 substituents independently selected from  $\text{R}^4$ ;
  - (d)  $\text{C}_3\text{-C}_8$  cycloalkenyl, optionally substituted with 1-2 substituents independently selected from  $\text{R}^4$ ;
  - 25 (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-,  $\text{-NR}^2$ - and  $\text{-S(O)}_n$ -, optionally substituted with 1-3 substituents independently selected from  $\text{R}^4$ ;


(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR<sup>2</sup>- and -S(O)<sub>n</sub>-, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>; or

- (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR<sup>2</sup>- and -S(O)<sub>n</sub>-, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>;

Z<sup>1</sup> is

- (a) -(CH<sub>2</sub>)<sub>p</sub> W(CH<sub>2</sub>)<sub>q</sub>-;  
 (b) -O(CH<sub>2</sub>)<sub>p</sub> CR<sup>5</sup>R<sup>6</sup>-;  
 (c) -O(CH<sub>2</sub>)<sub>p</sub>W(CH<sub>2</sub>)<sub>q</sub>-;  
 (d) -OCHR<sup>2</sup>CHR<sup>3</sup>-; or  
 (e) -SCHR<sup>2</sup>CHR<sup>3</sup>-;

G is

- (a) -NR<sup>7</sup>R<sup>8</sup>;  
 (b) 

wherein n is 0, 1 or 2; m is 1, 2 or 3; Z<sup>2</sup> is -NH-, -O-, -S-, or -CH<sub>2</sub>-;


optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and,

- optionally, independently on nitrogen with a chemically suitable substituent selected from R<sup>4</sup>; or

(c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>; or

- Z<sup>1</sup> and G in combination may be  
 W is

- (a) -CH<sub>2</sub>-;  
 (b) -CH=CH-;  
 (c) -O-;



(d)  $-\text{NR}^2-$ ;


(e)  $-\text{S}(\text{O})_n-$ ;

(f)  $\text{—}\overset{\text{O}}{\parallel}\text{C—}$  ;

(g)  $-\text{CR}^2(\text{OH})-$ ;

(h)  $-\text{CONR}^2-$ ;

(i)  $-\text{NR}^2\text{CO}-$ ;

(j)  ; or

(k)  $-\text{C}\equiv\text{C}-$ ;

R is hydrogen or  $\text{C}_1-\text{C}_6$  alkyl;

$\text{R}^2$  and  $\text{R}^3$  are independently

(a) hydrogen; or

(b)  $\text{C}_1-\text{C}_4$  alkyl;

$\text{R}^4$  is

(a) hydrogen;

(b) halogen;

(c)  $\text{C}_1-\text{C}_6$  alkyl;

(d)  $\text{C}_1-\text{C}_4$  alkoxy;

(e)  $\text{C}_1-\text{C}_4$  acyloxy;

(f)  $\text{C}_1-\text{C}_4$  alkylthio;

(g)  $\text{C}_1-\text{C}_4$  alkylsulfinyl;

(h)  $\text{C}_1-\text{C}_4$  alkylsulfonyl;

(i) hydroxy ( $\text{C}_1-\text{C}_4$ )alkyl;

(j) aryl ( $\text{C}_1-\text{C}_4$ )alkyl;

(k)  $-\text{CO}_2\text{H}$ ;

(l)  $-\text{CN}$ ;

(m)  $-\text{CONHOR}$ ;

(n)  $-\text{SO}_2\text{NHR}$ ;

(o)  $-\text{NH}_2$ ;

(p)  $\text{C}_1-\text{C}_4$  alkylamino;

(q)  $\text{C}_1-\text{C}_4$  dialkylamino;

(r)  $-\text{NHSO}_2\text{R}$ ;

- (s) -NO<sub>2</sub>;
- (t) -aryl; or
- (u) -OH;

R<sup>5</sup> and R<sup>6</sup> are independently C<sub>1</sub>-C<sub>8</sub> alkyl or together form a C<sub>3</sub>-C<sub>10</sub>

5 carbocyclic ring;

R<sup>7</sup> and R<sup>8</sup> are independently

- (a) phenyl;
- (b) a C<sub>3</sub>-C<sub>10</sub> carbocyclic ring, saturated or unsaturated;
- (c) a C<sub>3</sub>-C<sub>10</sub> heterocyclic ring containing up to two heteroatoms,
- 10 selected from -O-, -N- and -S-;
- (d) H;
- (e) C<sub>1</sub>-C<sub>8</sub> alkyl; or
- (f) form a 3 to 8 membered nitrogen containing ring with R<sup>5</sup> or

R<sup>6</sup>;

15 R<sup>7</sup> and R<sup>8</sup> in either linear or ring form may optionally be substituted with up to three substituents independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, halogen, alkoxy, hydroxy and carboxy;

a ring formed by R<sup>7</sup> and R<sup>8</sup> may be optionally fused to a phenyl ring;

e is 0, 1 or 2;

20 m is 1, 2 or 3;

n is 0, 1 or 2;


p is 0, 1, 2 or 3;

q is 0, 1, 2 or 3;

or an optical or geometric isomer thereof; or a pharmaceutically acceptable

25 salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

3. A method as in claim 2 wherein said estrogen agonist / antagonist is a compound of formula (IA):



5 wherein G is



$R^4$  is H, OH, F, or Cl; and B and E are independently selected from CH and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

15


4. A method as in claim 3 wherein said estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

20


5. A method as in claim 4 wherein said estrogen agonist / antagonist is in the form of a D-tartrate salt.

6. A method as in claim 1 wherein said estrogen agonist / antagonist is selected from the group consisting of tamoxifen, 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, EM-652, EM-800, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

7. A method as in claim 1 wherein said estrogen agonist / antagonist is a compound selected from the formulas V or VI:



(V)



(VI)

wherein:

$R_{1B}$  is selected from H, OH,  $-O-C(O)-C_1-C_{12}$  alkyl (straight chain or branched),  $-O-C_1-C_{12}$  alkyl (straight chain or branched or cyclic), or halogens or  $C_1-C_4$  halogenated ethers,

$R_{2B}$ ,  $R_{3B}$ ,  $R_{4B}$ ,  $R_{5B}$ , and  $R_{6B}$  are independently selected from H, OH,  $-O-C(O)-C_1-C_{12}$  (straight chain or branched),  $-O-C_1-C_{12}$  (straight chain or branched or cyclic), halogens, or  $C_1-C_4$  halogenated ethers, cyano,  $C_1-C_6$  alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when  $R_{1B}$  is H,  $R_{2B}$  is not OH;

X<sub>A</sub> is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, cyano, nitro, trifluoromethyl, and halogen;

s is 2 or 3;

5 Y<sub>A</sub> is the moiety:



wherein:

- 10 a) R<sub>7B</sub> and R<sub>8B</sub> are independently selected from the group of H, C<sub>1</sub>-C<sub>6</sub> alkyl, or phenyl optionally substituted by CN, C<sub>1</sub>-C<sub>6</sub> alkyl (straight chain or branched), C<sub>1</sub>-C<sub>6</sub> alkoxy (straight chain or branched), halogen, -OH, -CF<sub>3</sub>, or -OCF<sub>3</sub>; or
- b) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>,
- 20 -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or
- c) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or
- 25 d) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl,


-CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub> R<sub>1B</sub>,  
-NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

- e) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>,  
10 -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

- f) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents  
15 independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub> H, -CN, - CONHR<sub>1B</sub>,  
-NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>) alkyl; or an optical or geometric isomer thereof;  
20 or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

8. A method as in claim 7 wherein said estrogen agonist / antagonist is the compound, TSE-424, of formula Va below:






(Va)

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.


5

9. A use as in claim 1 wherein said estrogen agonist / antagonist is EM-652 of formula III below or is EM-800 of formula IV below:



(III)

10



(IV)

- 5 or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
10. A method as in claim 1 further comprising co-administering a cyclic guanosine 3',5'-monophosphate elevator.
- 10 11. A method as in claim 8 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE<sub>v</sub> phosphodiesterase inhibitor.
12. A method as in claim 5 further comprising co-administering 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate salt.
- 15 13. A method as in claim 1 wherein said method substantially reduces the concomitant liability of adverse effects associated with estrogen administration.
- 20 14. A method as in claim 1 wherein said female sexual dysfunction is a condition selected from the group consisting of hypoactive sexual desire disorder, sexual arousal disorder, dyspareunia and vaginismus.

15. A kit for use by a consumer to treat female sexual dysfunction comprising:

(a) a pharmaceutical composition comprising an estrogen agonist / antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and optionally,


5 (b) a pharmaceutical composition comprising a cyclic guanosine 3',5'-monophosphate elevator and pharmaceutically acceptable carrier, vehicle or diluent; and optionally,

(c) instructions describing a method of using the pharmaceutical composition(s) to treat female sexual dysfunction,

10 wherein said estrogen agonist / antagonist and said cyclic guanosine 3',5'-monophosphate elevator may optionally be combined in the same pharmaceutical composition.

16. A kit as in claim 15 wherein said estrogen agonist / antagonist of the

15 following formula (I):



wherein:

20 A is selected from CH<sub>2</sub> and NR;

B, D and E are independently selected from CH and N;

Y is

(a) phenyl, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>;

25 (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>;

(c)  $C_3$ - $C_8$  cycloalkyl, optionally substituted with 1-2 substituents independently selected from  $R^4$ ;

(d)  $C_3$ - $C_8$  cycloalkenyl, optionally substituted with 1-2 substituents independently selected from  $R^4$ ;

5 (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, - $NR^2$ - and - $S(O)_n$ -, optionally substituted with 1-3 substituents independently selected from  $R^4$ ;

(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, - $NR^2$ - and - $S(O)_n$ -, optionally substituted with 1-3 substituents independently selected from  $R^4$ ; or

(g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, - $NR^2$ - and - $S(O)_n$ -, optionally substituted with 1-3 substituents independently selected from  $R^4$ ;


15  $Z^1$  is

- (a)  $-(CH_2)_p W(CH_2)_q$ ;
- (b)  $-O(CH_2)_p CR^5R^6$ ;
- (c)  $-O(CH_2)_p W(CH_2)_q$ ;
- (d)  $-OCHR^2CHR^3$ ; or
- (e)  $-SCHR^2CHR^3$ ;

20

G is

- (a)  $-NR^7R^8$ ;




- (b)

wherein n is 0, 1 or 2; m is 1, 2 or 3;  $Z^2$  is -NH-, -O-, -S-, or - $CH_2$ -;

25 optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from  $R^4$ ; or


(c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from  $R^4$ ; or




Z<sup>1</sup> and G in combination may be

W is

- (a) -CH<sub>2</sub>-;
- (b) -CH=CH-;
- (c) -O-;
- (d) -NR<sup>2</sup>-;
- (e) -S(O)<sub>n</sub>-;



- (g) -CR<sup>2</sup>(OH)-;
- (h) -CONR<sup>2</sup>-;
- (i) -NR<sup>2</sup>CO-;



- (k) -C≡C-;

R is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are independently

- (a) hydrogen; or
- (b) C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>4</sup> is

- (a) hydrogen;
- (b) halogen;
- (c) C<sub>1</sub>-C<sub>6</sub> alkyl;
- (d) C<sub>1</sub>-C<sub>4</sub> alkoxy;
- (e) C<sub>1</sub>-C<sub>4</sub> acyloxy;
- (f) C<sub>1</sub>-C<sub>4</sub> alkylthio;
- (g) C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl;
- (h) C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl;
- (i) hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- (j) aryl (C<sub>1</sub>-C<sub>4</sub>)alkyl;

- (k)  $-\text{CO}_2\text{H}$ ;  
 (l)  $-\text{CN}$ ;  
 (m)  $-\text{CONHOR}$ ;  
 (n)  $-\text{SO}_2\text{NHR}$ ;  
 5 (o)  $-\text{NH}_2$ ;  
 (p)  $\text{C}_1\text{-C}_4$  alkylamino;  
 (q)  $\text{C}_1\text{-C}_4$  dialkylamino;  
 (r)  $-\text{NH}\text{SO}_2\text{R}$ ;  
 (s)  $-\text{NO}_2$ ;  
 10 (t)  $-\text{aryl}$ ; or  
 (u)  $-\text{OH}$ ;

$\text{R}^5$  and  $\text{R}^6$  are independently  $\text{C}_1\text{-C}_8$  alkyl or together form a  $\text{C}_3\text{-C}_{10}$  carbocyclic ring;

$\text{R}^7$  and  $\text{R}^8$  are independently


- 15 (a) phenyl;  
 (b) a  $\text{C}_3\text{-C}_{10}$  carbocyclic ring, saturated or unsaturated;  
 (c) a  $\text{C}_3\text{-C}_{10}$  heterocyclic ring containing up to two heteroatoms,  
 selected from  $-\text{O}-$ ,  $-\text{N}-$  and  $-\text{S}-$ ;  
 (d)  $\text{H}$ ;  
 20 (e)  $\text{C}_1\text{-C}_6$  alkyl; or  
 (f) form a 3 to 8 membered nitrogen containing ring with  $\text{R}^5$  or  $\text{R}^6$ ;

$\text{R}^7$  and  $\text{R}^8$  in either linear or ring form may optionally be substituted with up to three substituents independently selected from  $\text{C}_1\text{-C}_6$  alkyl, halogen, alkoxy, hydroxy and carboxy;


- 25 a ring formed by  $\text{R}^7$  and  $\text{R}^8$  may be optionally fused to a phenyl ring;  
 e is 0, 1 or 2;  
 m is 1, 2 or 3;  
 n is 0, 1 or 2;  
 30 p is 0, 1, 2 or 3;  
 q is 0, 1, 2 or 3;

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

17. A kit as in claim 16 wherein said estrogen agonist / antagonist is a compound of formula (IA):



wherein G is



10

R<sup>4</sup> is H, OH, F, or Cl; and B and E are independently selected from CH

15 and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

18. A kit as in claim 17 wherein said estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or  
 20 an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.



19. A kit as in claim 18 wherein said estrogen agonist / antagonist is in the form of a D-tartrate salt.

25

20. A kit as in claim 15 wherein said estrogen agonist / antagonist is selected from the group consisting of tamoxifen, 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-  
 30 hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, EM-652, EM-800, GW 5638, GW 7604 and optical or geometric isomers thereof; and pharmaceutically

acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

21. A kit as in claim 15 wherein said estrogen agonist / antagonist is a compound selected from the formulas V or VI:



wherein:

$R_{1B}$  is selected from H, OH,  $-O-C(O)-C_1-C_{12}$  alkyl (straight chain or branched),  $-O-C_1-C_{12}$  alkyl (straight chain or branched or cyclic), or halogens or  $C_1-C_4$  halogenated ethers,

$R_{2B}$ ,  $R_{3B}$ ,  $R_{4B}$ ,  $R_{5B}$ , and  $R_{6B}$  are independently selected from H, OH,  $-O-C(O)-C_1-C_{12}$  (straight chain or branched),  $-O-C_1-C_{12}$  (straight chain or branched or cyclic), halogens, or  $C_1-C_4$  halogenated ethers, cyano,  $C_1-C_6$  alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when  $R_{1B}$  is H,  $R_{2B}$  is not OH;



$X_A$  is selected from H,  $C_1-C_6$  alkyl, cyano, nitro, trifluoromethyl, and halogen;

s is 2 or 3;

5  $Y_A$  is the moiety:



wherein:

- 10 a)  $R_{7B}$  and  $R_{8B}$  are independently selected from the group of H,  $C_1-C_6$  alkyl, or phenyl optionally substituted by CN,  $C_1-C_6$  alkyl (straight chain or branched),  $C_1-C_6$  alkoxy (straight chain or branched), halogen, -OH, -CF<sub>3</sub>, or -OCF<sub>3</sub>; or
- b)  $R_{7B}$  and  $R_{8B}$  are concatenated to form a five-membered saturated heterocycle
- 15 containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo,  $C_1-C_4$  alkyl, trihalomethyl,  $C_1-C_4$  alkoxy, trihalomethoxy,  $C_1-C_4$  acyloxy,  $C_1-C_4$  alkylthio,  $C_1-C_4$  alkylsulfinyl,  $C_1-C_4$  alkylsulfonyl, hydroxy ( $C_1-C_4$ )alkyl, -CO<sub>2</sub>H, -CN-, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH( $C_1-C_4$  alkyl), -N( $C_1-C_4$  alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>,
- 20 -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 ( $C_1-C_4$ )alkyl; or
- c)  $R_{7B}$  and  $R_{8B}$  are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen,
- 25 hydroxyl, halo,  $C_1-C_4$  alkyl, trihalomethyl,  $C_1-C_4$  alkoxy, trihalomethoxy,  $C_1-C_4$  acyloxy,  $C_1-C_4$  alkylthio,  $C_1-C_4$  alkylsulfinyl,  $C_1-C_4$  alkylsulfonyl, hydroxy ( $C_1-C_4$ )alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH( $C_1-C_4$  alkyl), -N( $C_1-C_4$  alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 ( $C_1-C_4$ )alkyl; or
- 30 d)  $R_{7B}$  and  $R_{8B}$  are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo,  $C_1-C_4$  alkyl, trihalomethyl,  $C_1-C_4$  alkoxy, trihalomethoxy,  $C_1-C_4$  acyloxy,  $C_1-C_4$  alkylthio,  $C_1-C_4$  alkylsulfinyl,  $C_1-C_4$  alkylsulfonyl, hydroxy ( $C_1-C_4$ )alkyl,


-CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub> R<sub>1B</sub>, -NHCOR<sub>1B</sub> -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

- e) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

- f) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub> H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>) alkyl;
- 20 or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

22. A kit as in claim 21 wherein said estrogen agonist / antagonist is the compound, TSE-424, of formula Va below:


25




(Va)

- or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

23. A kit as in claim 15 wherein said estrogen agonist / antagonist is EM-652 of formula III below or EM-800 of formula IV below:



(III)



(IV)

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

5

24. A kit as in claim 15 wherein said kit further comprising a pharmaceutical composition comprising a cyclic guanosine 3',5'-monophosphate elevator and a pharmaceutically acceptable carrier, vehicle or diluent.

10 25. A kit as in claim 24 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE<sub>V</sub> phosphodiesterase inhibitor.

26. A kit as in claim 25 wherein said kit further comprises a pharmaceutical composition comprising 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sulfonyl]-4-methylpiperazine citrate salt and a pharmaceutically acceptable carrier, vehicle or diluent.

27. A kit as in claim 15 further comprising instructions describing a method of using the pharmaceutical composition(s) to treat female sexual dysfunction wherein said instructions indicate that the kit substantially reduces the concomitant liability of adverse effects associated with estrogen administration.

20

28. A kit as in claim 15 wherein said female sexual dysfunction is a condition selected from the group consisting of hypoactive sexual desire disorder, sexual arousal disorder, dyspareunia and vaginismus.


5 29. A pharmaceutical composition comprising:

(a) an estrogen agonist / antagonist, and

(b) a cyclic guanosine 3',5'-monophosphate elevator.

30. A pharmaceutical composition as in claim 29 wherein said cyclic guanosine  
10 3',5'-monophosphate elevator is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sulfonyl]-4-methylpiperazine citrate salt.

31. A pharmaceutical composition as in claim 29 wherein said estrogen agonist  
15 / antagonist of the following formula (I):



(I)

wherein:

20 A is selected from CH<sub>2</sub> and NR;

B, D and E are independently selected from CH and N;

Y is

(a) phenyl, optionally substituted with 1-3 substituents  
independently selected from R<sup>4</sup>;

25 (b) naphthyl, optionally substituted with 1-3 substituents  
independently selected from R<sup>4</sup>;

(c) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, optionally substituted with 1-2 substituents independently selected from R<sup>4</sup>;

(d) C<sub>3</sub>-C<sub>8</sub> cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R<sup>4</sup>;

5 (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR<sup>2</sup>- and -S(O)<sub>n</sub>-, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>;

(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR<sup>2</sup>- and -S(O)<sub>n</sub>-, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>; or

10 (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR<sup>2</sup>- and -S(O)<sub>n</sub>-, optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>;

15 Z<sup>1</sup> is

(a) -(CH<sub>2</sub>)<sub>p</sub> W(CH<sub>2</sub>)<sub>q</sub>-;

(b) -O(CH<sub>2</sub>)<sub>p</sub> CR<sup>5</sup>R<sup>6</sup>-;


(c) -O(CH<sub>2</sub>)<sub>p</sub> W(CH<sub>2</sub>)<sub>q</sub>-;

(d) -OCHR<sup>2</sup>CHR<sup>3</sup>-; or

20 (e) -SCHR<sup>2</sup>CHR<sup>3</sup>-;

G is


(a) -NR<sup>7</sup>R<sup>8</sup>;



wherein n is 0, 1 or 2; m is 1, 2 or 3; Z<sup>2</sup> is -NH-, -O-, -S-, or -CH<sub>2</sub>-;

25 optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R<sup>4</sup>; or

30 (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R<sup>4</sup>; or



Z<sup>1</sup> and G in combination may be

W is

5

- (a) -CH<sub>2</sub>-;
- (b) -CH=CH-;
- (c) -O-;
- (d) -NR<sup>2</sup>-;
- (e) -S(O)<sub>n</sub>-;

10

- (f) ;
- (g) -CR<sup>2</sup>(OH)-;
- (h) -CONR<sup>2</sup>-;
- (i) -NR<sup>2</sup>CO-;

- (j) ; or
- (k) -C≡C-;

R is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

15

R<sup>2</sup> and R<sup>3</sup> are independently

- (a) hydrogen; or
- (b) C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>4</sup> is

20

- (a) hydrogen;
- (b) halogen;
- (c) C<sub>1</sub>-C<sub>6</sub> alkyl;
- (d) C<sub>1</sub>-C<sub>4</sub> alkoxy;
- (e) C<sub>1</sub>-C<sub>4</sub> acyloxy;
- (f) C<sub>1</sub>-C<sub>4</sub> alkylthio;
- (g) C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl;
- (h) C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl;
- (i) hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- (j) aryl (C<sub>1</sub>-C<sub>4</sub>)alkyl;

25

- (k)  $-\text{CO}_2\text{H}$ ;  
 (l)  $-\text{CN}$ ;  
 (m)  $-\text{CONHOR}$ ;  
 (n)  $-\text{SO}_2\text{NHR}$ ;  
 5 (o)  $-\text{NH}_2$ ;  
 (p)  $\text{C}_1\text{-C}_4$  alkylamino;  
 (q)  $\text{C}_1\text{-C}_4$  dialkylamino;  
 (r)  $-\text{NHSO}_2\text{R}$ ;  
 (s)  $-\text{NO}_2$ ;  
 10 (t)  $-\text{aryl}$ ; or  
 (u)  $-\text{OH}$ ;

$\text{R}^5$  and  $\text{R}^6$  are independently  $\text{C}_1\text{-C}_6$  alkyl or together form a  $\text{C}_3\text{-C}_{10}$  carbocyclic ring;

$\text{R}^7$  and  $\text{R}^8$  are independently

- 15 (a) phenyl;  
 (b) a  $\text{C}_3\text{-C}_{10}$  carbocyclic ring, saturated or unsaturated;  
 (c) a  $\text{C}_3\text{-C}_{10}$  heterocyclic ring containing up to two heteroatoms,  
 selected from  $-\text{O}-$ ,  $-\text{N}-$  and  $-\text{S}-$ ;  
 (d)  $\text{H}$ ;  
 20 (e)  $\text{C}_1\text{-C}_6$  alkyl; or  
 (f) form a 3 to 8 membered nitrogen containing ring with  $\text{R}^5$  or  $\text{R}^6$ ;


$\text{R}^7$  and  $\text{R}^8$  in either linear or ring form may optionally be substituted with up to three substituents independently selected from  $\text{C}_1\text{-C}_6$  alkyl, halogen, alkoxy,

- 25 hydroxy and carboxy;  
 a ring formed by  $\text{R}^7$  and  $\text{R}^8$  may be optionally fused to a phenyl ring;  
 e is 0, 1 or 2;  
 m is 1, 2 or 3;  
 n is 0, 1 or 2;  
 30 p is 0, 1, 2 or 3;  
 q is 0, 1, 2 or 3;

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.



32. A pharmaceutical composition as in claim 31 wherein said estrogen agonist / antagonist is a compound of formula (IA):



wherein G is



15 33.  $R^4$  is H, OH, F, or Cl; and B and E are independently selected from CH and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

20 34. A pharmaceutical composition as in claim 32 wherein said estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.


25 35. A pharmaceutical composition as in claim 33 wherein said estrogen agonist / antagonist is in the form of a D-tartrate salt.

30 36. A pharmaceutical composition as in claim 29 wherein said estrogen agonist / antagonist is selected from the group consisting of tamoxifen, 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-


ethoxy]-phenyl)-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, EM-652, EM-800, GW 5638, GW 7604 and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

5

36. A pharmaceutical composition as in claim 29 wherein said estrogen agonist / antagonist is a compound selected from the formulas V or VI:



(V)



(VI)

15 wherein:

$R_{1B}$  is selected from H, OH,  $-O-C(O)-C_{1-12}$  alkyl (straight chain or branched),  $-O-C_{1-12}$  alkyl (straight chain or branched or cyclic), or halogens or  $C_1-C_4$  halogenated ethers,

$R_{2B}$ ,  $R_{3B}$ ,  $R_{4B}$ ,  $R_{5B}$ , and  $R_{6B}$  are independently selected from H, OH, -O-C(O)-  
C<sub>1</sub>-C<sub>12</sub> (straight chain or branched), -O-C<sub>1</sub>-C<sub>12</sub> (straight chain or branched or cyclic),  
halogens, or C<sub>1</sub>-C<sub>4</sub> halogenated ethers, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl (straight chain or  
branched), or trifluoromethyl, with the proviso that, when  $R_{1B}$  is H,  $R_{2B}$  is not OH;

5

$X_A$  is selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, cyano, nitro, trifluoromethyl, and halogen;

s is 2 or 3;

10

$Y_A$  is the moiety:



wherein:

15

a)  $R_{7B}$  and  $R_{8B}$  are independently selected from the group of H, C<sub>1</sub>-C<sub>6</sub> alkyl, or phenyl  
optionally substituted by CN, C<sub>1</sub>-C<sub>6</sub> alkyl (straight chain or branched), C<sub>1</sub>-C<sub>6</sub> alkoxy  
(straight chain or branched), halogen, -OH, -CF<sub>3</sub>, or -OCF<sub>3</sub>; or

20

b)  $R_{7B}$  and  $R_{8B}$  are concatenated to form a five-membered saturated heterocycle  
containing one nitrogen heteroatom, the heterocycle being optionally substituted with  
1-3 substituents independently selected from the group consisting of hydrogen,  
hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy,  
C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H,  
-CN-, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>,

25

-NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

c)  $R_{7B}$  and  $R_{8B}$  are concatenated to form a six-membered saturated heterocycle  
containing one nitrogen heteroatom, the heterocycle being optionally substituted with  
1-3 substituents independently selected from the group consisting of hydrogen,

30

hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy,  
C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H,  
-CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub>R<sub>1B</sub>, -NHCOR<sub>1B</sub>,  
-NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

d) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub> R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

e) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub>H, -CN, -CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub> R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>)alkyl; or

f) R<sub>7B</sub> and R<sub>8B</sub> are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trihalomethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, trihalomethoxy, C<sub>1</sub>-C<sub>4</sub> acyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, C<sub>1</sub>-C<sub>4</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub> alkylsulfonyl, hydroxy (C<sub>1</sub>-C<sub>4</sub>)alkyl, -CO<sub>2</sub> H, -CN, - CONHR<sub>1B</sub>, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, -NHSO<sub>2</sub> R<sub>1B</sub>, -NHCOR<sub>1B</sub>, -NO<sub>2</sub>, or phenyl optionally substituted with 1-3 (C<sub>1</sub>-C<sub>4</sub>) alkyl;

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

32. A pharmaceutical composition as in claim 25 further comprising a pharmaceutical composition comprising a cyclic guanosine 3',5'-monophosphate elevator.

33. A pharmaceutical composition as in claim 31 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE<sub>V</sub> phosphodiesterase inhibitor.

34. A pharmaceutical composition as in claim 29 further comprising a pharmaceutical composition comprising 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sulfonyl]-4-methylpiperazine citrate salt.

10  
20  
30  
40  
50  
60  
70  
80  
90  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
250  
260  
270  
280  
290  
300  
310  
320  
330  
340  
350  
360  
370  
380  
390  
400  
410  
420  
430  
440  
450  
460  
470  
480  
490  
500  
510  
520  
530  
540  
550  
560  
570  
580  
590  
600  
610  
620  
630  
640  
650  
660  
670  
680  
690  
700  
710  
720  
730  
740  
750  
760  
770  
780  
790  
800  
810  
820  
830  
840  
850  
860  
870  
880  
890  
900  
910  
920  
930  
940  
950  
960  
970  
980  
990  
1000